Venture Capital/News/ Asabys Partners announces €100m first close for health and biotech fund It’ll look to back around 12-15 startups in the UK, Europe, Israel and the US By Kai Nicol-Schwarz 15 February 2023 Asabys Partners Asabys Partners \Startup Life Techstars unexpectedly pulls out of Sweden mid-programme By Mimi Billing 23 March 2023 Venture Capital/News/ Asabys Partners announces €100m first close for health and biotech fund It’ll look to back around 12-15 startups in the UK, Europe, Israel and the US By Kai Nicol-Schwarz 15 February 2023 Barcelona-based health and life science-focused VC Asabys Partners is announcing a €100m first close of its second fund. It’s targeting a total of €200m — which it hopes to hit later this year — and will look to invest in startups with scientifically proven medical solutions. The first close came a couple of months later than the VC predicted when it announced it was raising for its second fund back in September — which could be a sign of the tricky fundraising landscape VCs are faced with at present. Where will the money be spent? Asabys Partners will invest €2m-5m in 12-15 startups in the UK, Europe, Israel and the US. The firm says it will invest up to €15m in follow-on rounds. Associate Maite Malet says the firm is particularly interested in investing in startups working on solutions in diagnostics and therapeutics segments like: Women’s health Neurology Chronic diseases Oncology Cardiology Immunology Where’s the money coming from? As with Asabys Partners’ first fund — which it raised in 2018 — Spanish banking group Banco Sabadell is the main private institutional investor. Other investors include the European Investment Fund — which recently announced a €3.75bn scaleup fund of funds — and Alantra. Asabys’s portfolio Asabys Partners was founded by Josep Sanfeliu — one of Spain’s most active angel investors in 2021 — and Clara Campàs. Since launching, the VC has backed 13 companies in the biopharma, medtech and digital health sectors and has around €217m assets-under-management, according to the firm. They include: Berlin-based gut health platform Cara Care, which raised $7m in June 2022. Iceland’s digital therapeutics startup Sidekick Health, which raised a $55m Series B in May 2022. Spanish startup Ona Therapeutics, which is developing novel therapies for metastatic cancer and raised €30m in June 2020. AgomAb Therapeutics, which is developing treatment to repair organ and tissue damage, raised a $40.5m Series B participated in by Pfizer. Kai Nicol-Schwarz is a reporter at Sifted. He tweets from @NicolSchwarzK. Related Articles Europe’s term sheets are getting even more founder-friendly By Eleanor Warnock Click here to read more Investors in European startups need a clearer path to exit By Nicolas Colin Click here to read more Best of Ukraine: 9 startups to watch, according to international investors By Zosia Wanat Click here to read more Investment into Spanish startups at record levels in 2022 By Tim Smith Click here to read more Most Read 1 \Startup Life UK government to reform ‘equity for visas’ residency application system 2 \Fintech Is Revolut really worth $33bn right now? 3 \Startup Life Techstars unexpectedly pulls out of Sweden mid-programme 4 \Deeptech The other funding gap: it’s not just unicorns that are leaving Europe 5 \Deeptech ‘There’s going to be a bloodbath’ — is generative AI a bubble?
Europe’s term sheets are getting even more founder-friendly By Eleanor Warnock Click here to read more
Best of Ukraine: 9 startups to watch, according to international investors By Zosia Wanat Click here to read more